Barclays PLC Buys 16,007 Shares of NeuroPace, Inc. (NASDAQ:NPCE)

Barclays PLC raised its stake in NeuroPace, Inc. (NASDAQ:NPCE) by 346.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,633 shares of the company’s stock after buying an additional 16,007 shares during the period. Barclays PLC owned about 0.07% of NeuroPace worth $144,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in NPCE. Financial Advocates Investment Management grew its holdings in shares of NeuroPace by 20.0% during the 3rd quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock valued at $125,000 after purchasing an additional 3,000 shares during the last quarter. XTX Topco Ltd grew its holdings in shares of NeuroPace by 56.1% during the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after purchasing an additional 8,643 shares during the last quarter. State Street Corp grew its holdings in shares of NeuroPace by 9.1% during the 3rd quarter. State Street Corp now owns 155,490 shares of the company’s stock valued at $1,084,000 after purchasing an additional 12,912 shares during the last quarter. Rhumbline Advisers bought a new position in shares of NeuroPace during the 2nd quarter valued at $111,000. Finally, Geode Capital Management LLC grew its holdings in shares of NeuroPace by 8.7% during the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock valued at $2,211,000 after purchasing an additional 25,330 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NPCE. Wells Fargo & Company cut their price target on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. JPMorgan Chase & Co. raised their price target on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Finally, UBS Group began coverage on shares of NeuroPace in a report on Tuesday. They issued a “buy” rating and a $17.00 price target on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.33.

NeuroPace Trading Up 7.5 %

NeuroPace stock opened at $14.04 on Thursday. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03. The company has a market cap of $419.09 million, a P/E ratio of -14.04 and a beta of 2.02. NeuroPace, Inc. has a 52-week low of $5.45 and a 52-week high of $18.15. The business has a 50-day simple moving average of $11.13 and a two-hundred day simple moving average of $8.52.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The firm had revenue of $21.06 million for the quarter, compared to the consensus estimate of $19.33 million. During the same period last year, the firm earned ($0.28) EPS. Analysts predict that NeuroPace, Inc. will post -1 EPS for the current year.

Insider Buying and Selling at NeuroPace

In other news, major shareholder Ltd. Kck sold 223,991 shares of NeuroPace stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $5.45, for a total value of $1,220,750.95. Following the completion of the transaction, the insider now owns 5,270,845 shares in the company, valued at approximately $28,726,105.25. The trade was a 4.08 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.20% of the stock is currently owned by company insiders.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.